 |
 |
 |
 |
 |
 |
|
||||||||||||||
Select Publications
Buzdar AU et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: An update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007;13(1):228-33. Abstract
Cataliotti L et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: The Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial. Cancer 2006;106(10):2095-103. Abstract
Dowsett M. Proliferation and apoptosis as measures of response. CTEP meeting: Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions. Bethesda, Maryland, March 26-27, 2007 http://ctep.cancer.gov/bcmeeting/ - agenda
Dowsett M et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer — A study from the IMPACT trialists. J Clin Oncol 2005;23(11):2477-92. Abstract
Ellis MJ et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. Cancer Res 2003;63(19):6523-31. Abstract
Gianni L et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis. Proc ASCO 2007;Abstract 532.
Goss PE et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;[Epub ahead of print]. Abstract
Ingle JN et al. Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Ann Oncol 2008;[Epub ahead of print]. Abstract
Press MF et al. HER-2/neu gene amplification characterized by f luorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15(8):2894-904. Abstract
Smith IE et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23(22):5108-16. Abstract
| Table of Contents | Top of Page |
INTERVIEWS
Neil Love, MD
Editor
Monica Morrow, MD
- Select publications
Ian E Smith, MD
- Select publications
Robert W Carlson, MD
- Select publications
Soonmyung Paik, MD
- Select publications
Breast Cancer Update
for Surgeons:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
